Tirzepatide
What 2,756 indexed publications and 131 randomized trials actually state about tirzepatide, sentence by sentence, each tied to its source and labeled by the kind of evidence it is.
Approved label 28 sources Updated Also: Mounjaro, Mounjaro (autoinjector), Zepbound
At a glance
Evidence availability
Approved label
Regulator-reviewed label exists
Indexed publications
2,756
Europe PMC, title or abstract, 2026-09-14
Human studies in ledger
22
20 randomized; study count, not efficacy proof
Approval
2022
ChEMBL phase 4 · ATC A10BX16
Routes reported
subcutaneous
from studies in this ledger
Studied in
Humans
23 primary studies in the evidence table
Compiled from 28 indexed sources, updated . Cited findings carry an evidence tier; passages written from general knowledge are marked editorial synthesis. Nothing here is medical or dosing advice. What changed
What it is
Tirzepatide is a peptide in the incretin & amylin analogs class (GIP and GLP-1 receptor dual agonist). Europe PMC indexes 2,756 publications naming it or a listed alias in a title or abstract, including 131 randomized controlled trials and 109 clinical trials of any design, as of . The strongest evidence tier in that literature is an approved medicine with a regulator-reviewed label.
This page reports what those studies state, sentence by sentence, with each statement tied to its source and labeled by the kind of evidence it is. It does not recommend use, and it does not translate study doses into anything personal.
What the evidence level means
Publication counts show what is indexed, not how strong the evidence is. The ledger below separates human clinical records from preclinical, analytical, and in-vitro work.
Human clinical studies in this ledger2220 randomized · 2 other human clinical
Evidence strengthNot yet assessedSeparate from evidence availability
Efficacy signalNot yet assessedRead the study result, not the tier alone
Interpretation boundary: An indexed publication count is a discovery measure. It does not establish efficacy, safety, approval, or a personal treatment plan.
What the evidence shows
One row per primary study in this record's ledger. Fields are read from each paper's indexing and abstract. "Analytical method" marks papers about detecting or measuring the compound rather than about its effects.
| Study | Design | n | Species | Dose | Route | Duration | Reported outcome | Tier |
|---|---|---|---|---|---|---|---|---|
| Falcon 2026 | Randomized controlled trial | — | Humans | 10 mg | — | — | Overall, most participants experienced an improvement in AHI severity category with tirzepatide treatment (68% to 79%), while the majority in the placebo group saw no clinically relevant change (64% to 70%). | Human clinical trial |
| Cusi 2026 | Randomized controlled trial | — | Humans | — | — | 52 week | Tirzepatide-treated participants experienced significant reductions in LFC, weight, HbA 1c , and overall greater improvement in lipids and liver enzymes regardless of the presence of PNPLA3 I148M allele. | Human clinical trial |
| Sattar 2026 | Randomized controlled trial | — | Humans | — | — | — | Across the trials, 32-38% vs 2-8% of tirzepatide-treated vs placebo-treated participants achieved ≥5% body weight reduction, systolic blood pressure reduction ≥5 mmHg, and non-HDL-C Conclusion In this post hoc analysis… | Human clinical trial |
| Lebwohl 2026 | Randomized controlled trial | — | Humans | — | — | — | Overall, 27.1% of participants simultaneously achieved PASI 100 and a 10% or greater weight reduction with ixekizumab plus tirzepatide vs 5.8% with ixekizumab (risk difference [RD], 21.2%; 95% CI, 12.8%-29.7%; P… | Human clinical trial |
| Sattar 2026 | Randomized controlled trial | 392 | Humans | — | — | 24 weeks; 72 weeks | At week 72, tirzepatide was associated with significantly greater reductions (negative values) or increases (positive values) in biomarker geometric means compared with placebo. | Human clinical trial |
| Nissen 2026 | Randomized controlled trial | 6,586 | Humans | 15 mg | subcutaneous | — | After a median (IQR) treatment duration of 46.9 (34.6-50.6) months, the primary cardiorenal end point occurred in 1559 tirzepatide-treated patients (23.7%) and 1803 dulaglutide-treated patients (27.4%; hazard ratio… | Human clinical trial |
| Kitamoto 2026 | Randomized controlled trial | 190 | Humans | 15 mg | — | — | At Week 72, the least-squares mean (LSM) percent change in body weight was significantly greater for tirzepatide (-20.1% [SE 0.76%]) versus semaglutide (-12.9% [0.74%]), with an LSM difference of -7.2 (95% CI = -9.3 to… | Human clinical trial |
| Kokkinos 2026 | Randomized controlled trial | 1,775 | Humans | — | — | — | In this post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials, tirzepatide-treated participants with obesity or overweight in both ER and non-ER groups achieved clinically meaningful weight reduction and… | Human clinical trial |
| Horn 2026 | Randomized controlled trial | 441 | Humans | 10 mg; 5 mg | subcutaneous | 24 weeks | From Sept 20, 2023, to Jan 20, 2026, 441 patients were enrolled in and took at least one dose of study treatment during the weight-loss period, with 378 participants randomly allocated at week 60 (140 to tirzepatide… | Human clinical trial |
| Pratley 2026 | Randomized controlled trial | 102 | Humans | — | — | 16 weeks | In participants receiving apitegromab, trough concentrations of apitegromab and total latent myostatin, a pharmacodynamic marker, both increased over time and reached a plateau after approximately 16 weeks. | Human clinical trial |
| Yang 2026 | Randomized controlled trial | — | Humans | 5 mg once weekly | — | 16 weeks | After 16 weeks of treatment, compared with the MET group, the COM group resulted in greater reductions in weight (-1.7 ± 2.5 kg vs. -10.4 ± 3.5 kg; p 2 ; p 2 ; p Conclusions In overweight/obese women with PCOS,… | Human clinical trial |
| Sattar 2026 | Randomized controlled trial | 538 | Humans | — | — | — | After 72 weeks of tirzepatide (10/15 mg), 16.7% of participants achieved a WHtR ≤ 0.49, and 54.7% improved their baseline WHtR category compared to 9.6% with placebo. | Human clinical trial |
| Aronne 2026 | Randomized controlled trial | 205 | Humans | — | — | — | 4.42) of body weight reduction with orforglipron compared with an MBE of 37.6% (s.e.m. | Human clinical trial |
| Masuzaki 2026 | Randomized controlled trial | 63 | Humans | 10 mg; 15 mg | — | — | In Japanese adults with obesity disease, tirzepatide significantly improved HR-QoL over 72 weeks compared with placebo in both physical and psychosocial domains. | Human clinical trial |
| Violante-Ortiz 2026 | Randomized controlled trial | — | Humans | — | — | — | In this subgroup analysis of SURPASS-SWITCH, switching to tirzepatide from dulaglutide was generally well-tolerated and associated with significant and consistent improvements in HbA1c and weight reductions versus… | Human clinical trial |
| Ishigaki 2026 | Randomized controlled trial | — | Humans | — | — | — | Participants in the tirzepatide 5-, 10-, and 15-mg groups had a statistically significantly greater (all p Conclusions Once-weekly treatment with tirzepatide demonstrated significant reductions in body weight and… | Human clinical trial |
| Caussy 2025 | Randomized controlled trial | 190 | Humans | — | — | — | Weight reduction and metabolic improvements with tirzepatide treatment potentially contributed to disease modification in MASH. | Human clinical trial |
| Pieber 2025 | Randomized controlled trial | 42 | Humans | 15 mg | — | — | Cortisol and noradrenaline responses were delayed with tirzepatide, consistent with lower hypoglycemic symptom scores at nadir observed during tirzepatide treatment periods versus placebo (p=0.007). | Human clinical trial |
| Mari 2025 | Randomized controlled trial | 539 | Humans | — | — | 72 weeks | At week 72, tirzepatide treatment was associated with body weight reduction and improvements in insulin sensitivity and β-cell function measures overall and in participants with prediabetes or normoglycemia. | Human clinical trial |
| Martin 2025 | Randomized controlled trial | 114 | Humans | — | — | — | Tirzepatide reduced energy intake versus placebo at week 3 (estimated treatment difference -524.6 kcal (95% confidence interval -648.1 to -401.0), P < 0.0001). | Human clinical trial |
| Zheng 2025 | Human study | 45 | Humans | — | — | — | The primary outcomes include the reversal rate and time to remission (in months) of endometrial lesions, which are determined through endometrial pathology sampling every 3 months, as well as the percentage of weight… | Observational, human |
| Herman 2025 | Human study | — | Humans | — | — | 24 weeks | — | Observational, human |
| Al 2026 | In vitro study | 60 | Humans | — | — | — | Medication for the disease of obesity has improved, and clinical trials based on natural gut hormones such as tirzepatide, showed only mild side effects and ~22% weight loss maintenance. | Mechanistic, in vitro |
Doses reported in studies
Each entry is a sentence quoted from the study's abstract, with the study's design, sample size and year in front of it. Comparator doses in the same sentence are not attributed to tirzepatide.
- Doses stated in the abstract: 10 mg
These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m 2 ) over a 52-week period.
Sourcepmid-42675225· quoted verbatim from the abstract, emphasis added - Doses stated in the abstract: 15 mg
Participants were randomized to receive subcutaneous tirzepatide up to 15 mg (n = 6586) or a fixed dose of dulaglutide, 1.5 mg (n = 6579), administered weekly.
Sourcepmid-41903177· quoted verbatim from the abstract, emphasis added - Doses stated in the abstract: 15 mg
Of 750 participants, 383 met the criteria for obesity disease (tirzepatide 15 mg or maximum tolerated dose [MTD], n = 190; semaglutide 2.4 mg or MTD, n = 193).
Sourcepmid-42434924· quoted verbatim from the abstract, emphasis added - Doses stated in the abstract: 10 mg; 5 mg
After completing the initial weight-loss period with once weekly subcutaneous tirzepatide at the MTD (10 mg or 15 mg), adults (aged ≥18 years) with a BMI of 30 kg/m 2 and above or 27 kg/m 2 and above with one or more weight-related comorbidity, and a history of at least one self-reported unsuccessful dietary effort to lose bodyweight were randomly assigned in a 3:3:2 ratio to continue tirzepatide MTD, reduce to tirzepatide 5 mg, or switch to placebo for an additional 52 weeks.
Sourcepmid-42119587· quoted verbatim from the abstract, emphasis added - Doses stated in the abstract: 5 mg once weekly
Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks.
Sourcepmid-42236268· quoted verbatim from the abstract, emphasis added - Doses stated in the abstract: 10 mg; 15 mg
Prespecified analyses assessed changes from baseline to Week 72 in HR-QoL using the Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) and 36-Item Short-Form Health Survey Version 2.0 (SF-36v2), and assessed subgroup differences by sex (male, female), baseline body mass index ( 2 ) and age ( Results Among 201 participants (tirzepatide 10 mg: n = 63; tirzepatide 15 mg: n = 69; placebo: n = 69), both tirzepatide doses significantly improved IWQOL-Lite-CT Physical Function composite, Physical composite, Psychosocial composite and Total scores and the SF-36v2 Physical Functioning domain score at Week 72 versus placebo.
Sourcepmid-42108080· quoted verbatim from the abstract, emphasis added
Escalation schedules used in studies
How trials stepped doses, reported as study design.
-
Participants were randomly assigned 1:1 to continue with and escalate to dulaglutide 4.5 mg or maximum tolerated dose (MTD) or switch to tirzepatide with escalation to 15 mg or MTD.
Sourcepmid-41912265· quoted verbatim from the abstract
Adverse events and frequency
Events and their frequency as each study reported them, with the denominator where the abstract gives one.
-
After a median (IQR) treatment duration of 46.9 (34.6-50.6) months, the primary cardiorenal end point occurred in 1559 tirzepatide-treated patients (23.7%) and 1803 dulaglutide-treated patients (27.4%; hazard ratio [HR], 0.84; 95% CI, 0.79-0.90; P Conclusions In this post hoc analysis, the dual GLP-1 and GIP agonist tirzepatide, compared with the GLP-1 agonist dulaglutide, was associated with a lower incidence of a broad 6-component composite cardiovascular and kidney end point in patients with diabetes and established cardiovascular disease.
Sourcepmid-41903177· quoted verbatim from the abstract -
We aimed to assess weight reduction, CRPs, tolerability and hypoglycaemia according to early body weight response to tirzepatide in these studies.
Sourcepmid-42348366· quoted verbatim from the abstract -
The primary estimand was the modified treatment-regimen estimand, which assumed that participants who initiated rescue tirzepatide would not have gained further benefit from their assigned study treatment and included all randomly allocated participants, regardless of treatment discontinuation or initiation of prohibited medications.
Sourcepmid-42119587· quoted verbatim from the abstract -
In summary, this proof-of-concept study demonstrated that selective targeting of myostatin by apitegromab was well tolerated and effective in preserving lean mass when combined with tirzepatide.
Sourcepmid-42260100· quoted verbatim from the abstract -
In this subgroup analysis of SURPASS-SWITCH, switching to tirzepatide from dulaglutide was generally well-tolerated and associated with significant and consistent improvements in HbA1c and weight reductions versus dulaglutide across all baseline subgroups evaluated.
Sourcepmid-41912265· quoted verbatim from the abstract -
To evaluate counterregulatory hormonal responses during a hypoglycemic clamp with tirzepatide.
Sourcepmid-40964167· quoted verbatim from the abstract
Study durations
Treatment and follow-up periods as stated in each abstract.
- Durations stated: 52 week
This post hoc analysis evaluated changes in MRI-assessed LFC and cardiometabolic parameters by presence (genotypes GG and CG) or absence (genotype CC) of the PNPLA3 I148M allele after 52-week treatment.
Sourcepmid-42576670· quoted verbatim from the abstract - Durations stated: 24 weeks; 72 weeks
The aforementioned biomarkers were assayed from plasma samples, collected at baseline, 24 weeks, and 72 weeks, from 100 randomly selected participants from each group of the SURMOUNT-1 trial who completed treatment with once-weekly placebo or tirzepatide 5, 10, or 15 mg (n = 392 after low sample volumes excluded).
Sourcepmid-42233927· quoted verbatim from the abstract, emphasis added - Durations stated: 24 weeks
Starting at week 84 (24 weeks after random allocation), participants could receive rescue tirzepatide if their weight regain exceeded 50%.
Sourcepmid-42119587· quoted verbatim from the abstract, emphasis added - Durations stated: 16 weeks
In participants receiving apitegromab, trough concentrations of apitegromab and total latent myostatin, a pharmacodynamic marker, both increased over time and reached a plateau after approximately 16 weeks.
Sourcepmid-42260100· quoted verbatim from the abstract, emphasis added - Durations stated: 16 weeks
After 16 weeks of treatment, compared with the MET group, the COM group resulted in greater reductions in weight (-1.7 ± 2.5 kg vs. -10.4 ± 3.5 kg; p 2 ; p 2 ; p Conclusions In overweight/obese women with PCOS, low-dose tirzepatide combined with MET was associated with greater reductions in body weight and visceral fat, along with improvements in metabolic and reproductive outcomes compared with MET monotherapy.
Sourcepmid-42236268· quoted verbatim from the abstract, emphasis added - Durations stated: 72 weeks
We assessed insulin sensitivity and β-cell function in adults with obesity/overweight, without diabetes, treated with tirzepatide for 72 weeks.
Sourcepmid-40694530· quoted verbatim from the abstract, emphasis added
Routes studied
Routes of administration named in each study.
- administration by subcutaneous route reported
Participants were randomized to receive subcutaneous tirzepatide up to 15 mg (n = 6586) or a fixed dose of dulaglutide, 1.5 mg (n = 6579), administered weekly.
Sourcepmid-41903177· quoted verbatim from the abstract - administration by subcutaneous route reported
After completing the initial weight-loss period with once weekly subcutaneous tirzepatide at the MTD (10 mg or 15 mg), adults (aged ≥18 years) with a BMI of 30 kg/m 2 and above or 27 kg/m 2 and above with one or more weight-related comorbidity, and a history of at least one self-reported unsuccessful dietary effort to lose bodyweight were randomly assigned in a 3:3:2 ratio to continue tirzepatide MTD, reduce to tirzepatide 5 mg, or switch to placebo for an additional 52 weeks.
Sourcepmid-42119587· quoted verbatim from the abstract
Reported interactions
Sentences in which the compound is studied alongside another agent. Read the quotation: the word interaction can also be statistical.
-
Overall, 27.1% of participants simultaneously achieved PASI 100 and a 10% or greater weight reduction with ixekizumab plus tirzepatide vs 5.8% with ixekizumab (risk difference [RD], 21.2%; 95% CI, 12.8%-29.7%; P Conclusions and relevance The trial results suggest that concomitant ixekizumab and tirzepatide produced clinically meaningful, statistically significant improvements in skin clearance and reductions in weight in participants with moderate to severe psoriasis, with no new safety concerns, while providing additional cardiometabolic benefits and a potential to elevate care.
Sourcepmid-42139049· quoted verbatim from the abstract -
In summary, this proof-of-concept study demonstrated that selective targeting of myostatin by apitegromab was well tolerated and effective in preserving lean mass when combined with tirzepatide.
Sourcepmid-42260100· quoted verbatim from the abstract -
This study aimed to assess the effects of low-dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS).
Sourcepmid-42236268· quoted verbatim from the abstract -
This trial aims to explore the synergistic effects and safety of tirzepatide combined with standard fertility-preserving treatment for endometrial lesions.
Sourcepmid-41198197· quoted verbatim from the abstract
Exclusion criteria in studies
Who each trial excluded, as stated in the abstract.
-
The aforementioned biomarkers were assayed from plasma samples, collected at baseline, 24 weeks, and 72 weeks, from 100 randomly selected participants from each group of the SURMOUNT-1 trial who completed treatment with once-weekly placebo or tirzepatide 5, 10, or 15 mg (n = 392 after low sample volumes excluded).
Sourcepmid-42233927· quoted verbatim from the abstract -
To evaluate the efficacy and safety of tirzepatide versus semaglutide in individuals eligible for pharmacotherapy for obesity disease under Japan's national insurance criteria, where obesity is defined as body mass index (BMI) ≥25 kg/m 2 with excess adiposity.
Sourcepmid-42434924· quoted verbatim from the abstract
Biomarkers measured in studies
Laboratory and clinical measures the studies report tracking, including which hormones did and did not change.
-
Given that excess adiposity is a known risk factor for OSA, we aimed to descriptively assess the association of tirzepatide, a GIP/GLP-1 receptor agonist, with changes in AHI, hypoxic burden, body weight, and blood pressure in different patient populations based on baseline characteristics such as age, sex, BMI, AHI, and neck circumference.
Sourcepmid-42675225· quoted verbatim from the abstract -
In the SURPASS-3 MRI substudy, tirzepatide significantly reduced liver fat content (LFC) versus insulin degludec in insulin-naïve patients with type 2 diabetes with metabolic dysfunction-associated steatotic liver disease.
Sourcepmid-42576670· quoted verbatim from the abstract -
In the SURMOUNT clinical trial program, once-weekly tirzepatide resulted in substantial body weight reductions in people with obesity, without and with type 2 diabetes.
Sourcepmid-42594122· quoted verbatim from the abstract -
Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes and obesity.
Sourcepmid-42233927· quoted verbatim from the abstract -
The dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide was noninferior to a GLP-1 agonist, dulaglutide, for effects on the composite outcome of cardiovascular death, myocardial infarction (MI), or stroke.
Sourcepmid-41903177· quoted verbatim from the abstract -
To evaluate the efficacy and safety of tirzepatide versus semaglutide in individuals eligible for pharmacotherapy for obesity disease under Japan's national insurance criteria, where obesity is defined as body mass index (BMI) ≥25 kg/m 2 with excess adiposity.
Sourcepmid-42434924· quoted verbatim from the abstract
Reported timelines
Onset, peak and duration figures as each study reported them.
-
After 16 weeks of treatment, compared with the MET group, the COM group resulted in greater reductions in weight (-1.7 ± 2.5 kg vs. -10.4 ± 3.5 kg; p 2 ; p 2 ; p Conclusions In overweight/obese women with PCOS, low-dose tirzepatide combined with MET was associated with greater reductions in body weight and visceral fat, along with improvements in metabolic and reproductive outcomes compared with MET monotherapy.
Sourcepmid-42236268· quoted verbatim from the abstract -
After 72 weeks of tirzepatide (10/15 mg), 16.7% of participants achieved a WHtR ≤ 0.49, and 54.7% improved their baseline WHtR category compared to 9.6% with placebo.
Sourcepmid-42082865· quoted verbatim from the abstract
Method note · shared across compounds
Reconstitution mathematics
Lyophilised peptide is supplied as a mass in a vial and dissolved in a stated volume of diluent. Two figures follow from that and nothing else:
- Concentration = mass in vial ÷ diluent volume. A 5 mg vial in 2 mL is 2.5 mg/mL, or 2,500 mcg/mL.
- Volume for a given mass = that mass ÷ concentration. 250 mcg at 2,500 mcg/mL is 0.1 mL. On a U-100 insulin syringe, where 1 mL is 100 units, that is 10 units.
Study doses on this page are quoted as published, in the units the authors used. Converting between mcg, mg and IU, or between a mass and a syringe volume, is arithmetic; deciding a mass is not, and this page does not do it. The reconstitution calculator performs the conversion with the formula shown.
Method note · shared across compounds
Reading a certificate of analysis
A certificate of analysis is a laboratory report on one batch. Reading it means checking four things in order.
- Identity. Mass spectrometry should report an observed molecular mass matching the peptide's theoretical mass within the instrument's stated tolerance. A certificate with no mass spectrometry, or one that lists only the expected value, has not confirmed identity.
- Purity. HPLC purity is the area of the main peak as a share of all peaks, at a stated wavelength. It says nothing about what the other peaks are, and it is not a measure of quantity.
- Quantity. Net peptide content, by amino acid analysis or UV, is the fraction of the vial's mass that is peptide rather than counter-ions and water. A 5 mg vial at 80% net content holds 4 mg of peptide, and every concentration figure above changes accordingly.
- Provenance. The batch number on the certificate should match the vial, the laboratory should be named and independent of the seller, and the test date should be recent.
This page rates no supplier and links to none. It describes how to read the document.
Method note · shared across compounds
Equipment described in studies
Published human studies of injectable peptides report the same small set of materials: single-use insulin syringes with fixed needles, most often U-100 with 29 to 31 gauge needles; bacteriostatic water or sterile water for injection as diluent, with the choice stated in the methods; alcohol swabs; and refrigerated storage of reconstituted solution. Animal studies more often report intraperitoneal or intragastric administration and state the vehicle used. Where a study in this record's ledger names its materials or vehicle, that sentence appears under storage or routes above; where it does not, nothing is assumed here.
Other compounds in its class
Same class in the registry: Cagrilintide, Retatrutide, Semaglutide, Survodutide. Each row shows what that compound's own record states; nothing is inferred across rows. Head-to-head evidence, where any exists, is on the comparison pages: Semaglutide vs Tirzepatide, Retatrutide vs Tirzepatide.
| Compound | Tier | Publications | RCTs | Record |
|---|---|---|---|---|
| Tirzepatide | Approved label | 2,756 | 131 | draft |
| Cagrilintide | Human clinical trial | 105 | 15 | draft |
| Retatrutide | Human clinical trial | 197 | 7 | draft |
| Semaglutide | Approved label | 6,039 | 305 | draft |
| Survodutide | Human clinical trial | 91 | 10 | draft |
Regulatory status
Registry facts only. Jurisdiction-level status, compounding categories and sport prohibitions need their own cited documents before they appear here.
- Registry entry
Open questions and limitations
What is genuinely unknown, stated plainly. A missing field is not evidence that the outcome is safe, effective, or established.
- No study in this record's ledger reports weight-normalized doses for Tirzepatide.
- No study in this record's ledger reports storage or stability for Tirzepatide.
Questions people ask
Has Tirzepatide been tested in humans?
Yes. Europe PMC indexes 109 clinical trials and 131 randomized controlled trials naming Tirzepatide or a listed alias in the title or abstract. The evidence table above lists the ones in this record's ledger with their design and sample size; check the study name, since an alias can refer to a different formulation of the same molecule.
What kind of evidence exists for Tirzepatide?
The strongest tier is approved label: an approved medicine with a regulator-reviewed label. Every claim on this page carries its own tier, because a compound with one human trial and forty animal studies is described by both facts, not the better one.
Is Tirzepatide an approved medicine?
ChEMBL records CHEMBL4297839 at maximum clinical phase 4, first approved 2022. Approval status differs by jurisdiction and is pending human review on this record.
Which species has Tirzepatide been studied in?
Studies in this record's ledger report work in: Humans. Findings in one species do not transfer to another, and weight-normalized doses in particular do not scale linearly between them.
Sources
Full citations. Every claim above links to one of these by its id.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
pmid-42233927· · peer-reviewed - 9
- 10
- 11Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
pmid-42120723· · peer-reviewed - 12
Show the remaining 16 sources
- 13
- 14
- 15Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.
pmid-42082865· · peer-reviewed - 16
- 17Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.
pmid-41612966· · peer-reviewed - 18
- 19
- 20
- 21
- 22
- 23Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
pmid-40555748· · peer-reviewed - 24
- 25Obesity Management in Adults: A Review.
pmid-38015216· · peer-reviewed - 26Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.
pmid-36992862· · peer-reviewed - 27
- 28How May GIP Enhance the Therapeutic Efficacy of GLP-1?
pmid-32396843· · peer-reviewed
Reference card
Reference card · generated /compounds/tirzepatide
- Compound
- Tirzepatide, incretin and amylin analogs
- Evidence tier
- Approved label
- Indexed publications
- 2,756 · 131 RCTs · 109 other clinical trials
- Approval
- approved (2022) · ATC A10BX16
- Routes reported
- subcutaneous
Study figures are as published in each source and are not recommendations. Print or save this card with its date.
Last reviewed and what changed
Newest first. These are the record's own revision dates, and the same dates feed the sitemap.
- · Claims drafted extractively from 28 ledger sources by scripts/draft_claims.py: 35 claims, 23 evidence-table rows. Status researched -> draft.
- · Claims drafted extractively from 28 ledger sources by scripts/draft_claims.py: 36 claims, 23 evidence-table rows. Status researched -> draft.
- · Metadata refreshed by scripts/fetch_evidence.py --refresh-meta: tier human-clinical-trial -> approved-label; chembl None -> CHEMBL4297839.
- · Evidence fetched from Europe PMC and ChEMBL by scripts/fetch_evidence.py; claims not yet written.